YounossiZMStepanovaMAfendyM. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524-530.e1; quiz e60.
2.
YilmazY. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?Aliment Pharmacol Ther. 2012;36(9):815-823.
3.
EisenbergDMDavisRBEttnerSL. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-1575.
4.
FerrucciLMBellBPDhotreKB. Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol. 2010;44(2):e40-e45.
5.
StraderDBBaconBRLindsayKL. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol. 2002;97(9):2391-2397.
6.
HardwickRNFisherCDCanetMJLakeACherringtonNJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2010;38(12):2293-2301.
7.
RimbachGMoehringJHuebbePLodgeJK. Gene-regulatory activity of alpha-tocopherol. Molecules. 2010;15(3):1746-1761.
8.
SanyalAJChalasaniNKowdleyKV. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685.
9.
LavineJESchwimmerJBVan NattaML. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659-1668.
10.
MillerERPastor-BarriusoRDalalD. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46.
11.
BerryDWathenJKNewellM. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials. 2009;6(1):28-41.
12.
GerssJKopckeW. The questionable association of vitamin E supplementation and mortality—inconsistent results of different meta-analytic approaches. Cell Mol Biol (Noisy-le-grand). 2009;55(suppl):OL1111-OL1120.
